| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/09/2003 | WO2003002107A2 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 01/09/2003 | WO2003002103A2 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | WO2003002094A2 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2003001882A2 Putative neurotransmitter receptor (pnr) disruptions, compositions and methods relating thereto |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2002083716A3 Type b botulism toxin inhibitors |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002072536A8 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002051401A3 Controlled release formulations of divalproex sodium |
| 01/09/2003 | WO2002048092A3 Compounds for altering mitochondrial function and cellular responses |
| 01/09/2003 | WO2002047686A8 Substituted-4-quinolones |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002024726A3 Olfactory and pheromones g-protein coupled receptors |
| 01/09/2003 | WO2002022579A3 Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| 01/09/2003 | WO2002008407A3 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 01/09/2003 | WO2002007669A3 Phospholipid derivatives of valproic acid and mixtures thereof |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001097793A3 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009777 Using galanin agonist in the generation of medicament for the treatment of nerve damage |
| 01/09/2003 | US20030009038 Adding formaldehyde and terephthalic acid compound to fuming sulfuric acid containing al least 20% of SO3, heating the mixture, isolating carboxyphthalide compound |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008899 For use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008892 Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| 01/09/2003 | US20030008890 For therapy of neurological and psychological disorders |
| 01/09/2003 | US20030008889 Aminoadamantane derivatives as therapeutic agents |
| 01/09/2003 | US20030008886 For therapy of pain |
| 01/09/2003 | US20030008883 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 01/09/2003 | US20030008882 Proteomimetic compounds and methods |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008880 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| 01/09/2003 | US20030008879 For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008874 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008865 Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use |
| 01/09/2003 | US20030008863 Novel tricyclic diazepines tocolytic oxytocin receptor antagonists |
| 01/09/2003 | US20030008859 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/09/2003 | US20030008856 Treatment of septic shock |
| 01/09/2003 | US20030008852 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 01/09/2003 | US20030008842 Formulations of adenosine a1 agonists |
| 01/09/2003 | US20030008820 Methods and products related to FGF dimerization |
| 01/09/2003 | US20030008806 Inhibitors of phosphodiesterases (PDEs) such as papaverine for treatment of drug dependence and psychological disorders |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008354 Peptide for use in the diagnosis and treatment of parkinson's, cancer and developmental defects |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008273 Methods for increasing the survival of neuronal cells |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007965 Treatment of substance P-related disorders |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2452393A1 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452321A1 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452167A1 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2452039A1 Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| 01/09/2003 | CA2451959A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | CA2451850A1 Medicinal compositions |
| 01/09/2003 | CA2451795A1 Cell-based high-throughput screening methods |
| 01/09/2003 | CA2451728A1 Zonisamide use in headache |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451228A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | CA2451163A1 Agent for preventing or treating organ functional disorders and order dysfunction |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |